Lack of extracellular matrix switches TGF-β induced apoptosis of endometrial cells to epithelial to mesenchymal transition.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
18
03
2022
accepted:
23
08
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
The extracellular matrix and the correct establishment of epithelial cell polarity plays a critical role in epithelial cell homeostasis and cell polarity. In addition, loss of tissue structure is a hallmark of carcinogenesis. In this study, we have addressed the role of extracellular matrix in the cellular responses to TGF-β. It is well known that TGF-β is a double-edged sword: it acts as a tumor suppressor in normal epithelial cells, but conversely has tumor-promoting effects in tumoral cells. However, the factors that determine cellular outcome in response to TGF-β remain controversial. Here, we have demonstrated that the lack of extracellular matrix and consequent loss of cell polarity inhibits TGF-β-induced apoptosis, observed when endometrial epithelial cells are polarized in presence of extracellular matrix. Rather, in absence of extracellular matrix, TGF-β-treated endometrial epithelial cells display features of epithelial-to-mesenchymal transition. We have also investigated the molecular mechanism of such a switch in cellular response. On the one hand, we found that the lack of Matrigel results in increased AKT signaling which is sufficient to inhibit TGF-β-induced apoptosis. On the other hand, we demonstrate that TGF-β-induced epithelial-to-mesenchymal transition requires ERK and SMAD2/3 activation. In summary, we demonstrate that loss of cell polarity changes the pro-apoptotic function of TGF-β to tumor-associated phenotype such as epithelial-to-mesenchymal transition. These results may be important for understanding the dual role of TGF-β in normal versus tumoral cells.
Identifiants
pubmed: 36050359
doi: 10.1038/s41598-022-18976-1
pii: 10.1038/s41598-022-18976-1
pmc: PMC9437059
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14821Informations de copyright
© 2022. The Author(s).
Références
Cell Death Differ. 2017 Aug;24(8):1443-1458
pubmed: 28524854
Nat Cell Biol. 2007 Sep;9(9):1016-24
pubmed: 17762893
Hum Pathol. 2012 May;43(5):632-43
pubmed: 21940036
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Am J Pathol. 2010 Jun;176(6):2722-31
pubmed: 20395448
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
EMBO J. 2021 Sep 15;40(18):e108647
pubmed: 34459003
J Biochem. 2012 Oct;152(4):321-9
pubmed: 22923731
Curr Opin Cell Biol. 2009 Apr;21(2):166-76
pubmed: 19237272
J Cell Physiol. 2022 Jan;237(1):59-85
pubmed: 34286853
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Gynecol Oncol. 2004 Oct;95(1):173-80
pubmed: 15385128
Oncotarget. 2017 May 22;8(42):71400-71417
pubmed: 29069715
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36
pubmed: 7806579
J Cell Physiol. 2019 Feb 5;:
pubmed: 30723913
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3873-3882
pubmed: 30651315
Annu Rev Pathol. 2019 Jan 24;14:339-367
pubmed: 30332563
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Cell Res. 2009 Jan;19(1):89-102
pubmed: 19050696
Cancer Res. 2002 May 15;62(10):2778-90
pubmed: 12019154
Biomolecules. 2020 Mar 23;10(3):
pubmed: 32210029
Mol Cancer Ther. 2011 Aug;10(8):1357-66
pubmed: 21613448
Hum Pathol. 2013 Oct;44(10):1973-81
pubmed: 23845467
Trends Cell Biol. 2020 Oct;30(10):764-776
pubmed: 32800658
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3883-3892
pubmed: 30655341
Curr Opin Genet Dev. 2004 Feb;14(1):71-80
pubmed: 15108808
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):
pubmed: 28193725
J Cell Biochem. 2019 Mar;120(3):2782-2790
pubmed: 30321449
Curr Opin Cell Biol. 2003 Dec;15(6):753-62
pubmed: 14644202
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Curr Opin Cell Biol. 2018 Apr;51:1-7
pubmed: 29149681
Ann Transl Med. 2021 Oct;9(20):1601
pubmed: 34790807
Histopathology. 2011 Jul;59(1):63-72
pubmed: 21771027
Nat Rev Cancer. 2005 Sep;5(9):675-88
pubmed: 16148884
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200510
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
J Obstet Gynaecol Res. 2000 Jun;26(3):163-70
pubmed: 10932976
J Cell Sci. 2008 Apr 15;121(Pt 8):1141-50
pubmed: 18388309
Br J Pharmacol. 2019 Jan;176(1):82-92
pubmed: 29510460
PLoS Genet. 2011 Oct;7(10):e1002320
pubmed: 22028666
J Anim Sci Biotechnol. 2014 Nov 14;5(1):52
pubmed: 25478164
Int J Mol Sci. 2018 Apr 26;19(5):
pubmed: 29701666
J Clin Med. 2021 Aug 30;10(17):
pubmed: 34501347
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638474
J Pathol. 2017 Sep;243(1):89-99
pubmed: 28657664